Having trouble accessing articles? Reset your cache.

Arcutis gains in this year’s third biotherapeutic IPO on NASDAQ

The aftermarket performance of two IPOs in January’s final week suggests investors’ appetite for new biotech listings remains robust.

In NASDAQ’s third biotherapeutic IPO of the year, dermatology company Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) raised $159.4 million through the sale of 9.4 million shares at $17,

Read the full 444 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE